# A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

> **NCT06693908** · PHASE1,PHASE2 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Moderate to Severe Ulcerative Colitis

## Interventions

- **DRUG:** Vixarelimab

## Key facts

- **NCT ID:** NCT06693908
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-06-09
- **Final completion:** 2026-08-16
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693908, "A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT06693908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*